Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Dec;72(6):1364–1372. doi: 10.1038/bjc.1995.516

Preparation and preclinical evaluation of humanised A33 immunoconjugates for radioimmunotherapy.

D J King 1, P Antoniw 1, R J Owens 1, J R Adair 1, A M Haines 1, A P Farnsworth 1, H Finney 1, A D Lawson 1, A Lyons 1, T S Baker 1, et al.
PMCID: PMC2034099  PMID: 8519646

Abstract

A humanised IgG1/k version of A33 (hA33) has been constructed and expressed with yields up to 700 mg l-1 in mouse myeloma NS0 cells in suspension culture. The equilibrium dissociation constant of hA33 (KD = 1.3 nM) was shown to be equivalent to that of the murine antibody in a cell-binding assay. hA33 labelled with yttrium-90 using the macrocyclic chelator 12N4 (DOTA) was shown to localise very effectively to human colon tumour xenografts in nude mice, with tumour levels increasing as blood concentration fell up to 144 h. A Fab' variant of hA33 with a single hinge thiol group to facilitate chemical cross-linking has also been constructed and expressed with yields of 500 mg l-1. Trimaleimide cross-linkers have been used to produce a trivalent Fab fragment (hA33 TFM) that binds antigen on tumour cells with greater avidity than hA33 IgG. Cross-linkers incorporating 12N4 or 9N3 macrocycles have been used to produce hA33 TFM labelled stably and site specifically with yttrium-90 or indium-111 respectively. These molecules have been used to demonstrate that hA33 TFM is cleared more rapidly than hA33 IgG from the circulation of animals but does not lead to accumulation of these metallic radionuclides in the kidney. 90Y-labelled hA33 TFM therefore appears to be the optimal form of the antibody for radioimmunotherapy of colorectal carcinoma.

Full text

PDF
1364

Images in this article

1367Figure 3
on p.1367

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bebbington C. R., Renner G., Thomson S., King D., Abrams D., Yarranton G. T. High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker. Biotechnology (N Y) 1992 Feb;10(2):169–175. doi: 10.1038/nbt0292-169. [DOI] [PubMed] [Google Scholar]
  2. Brown B. A., Comeau R. D., Jones P. L., Liberatore F. A., Neacy W. P., Sands H., Gallagher B. M. Pharmacokinetics of the monoclonal antibody B72.3 and its fragments labeled with either 125I or 111In. Cancer Res. 1987 Feb 15;47(4):1149–1154. [PubMed] [Google Scholar]
  3. Burton D. R., Woof J. M. Human antibody effector function. Adv Immunol. 1992;51:1–84. doi: 10.1016/s0065-2776(08)60486-1. [DOI] [PubMed] [Google Scholar]
  4. Caron P. C., Co M. S., Bull M. K., Avdalovic N. M., Queen C., Scheinberg D. A. Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Res. 1992 Dec 15;52(24):6761–6767. [PubMed] [Google Scholar]
  5. Co M. S., Deschamps M., Whitley R. J., Queen C. Humanized antibodies for antiviral therapy. Proc Natl Acad Sci U S A. 1991 Apr 1;88(7):2869–2873. doi: 10.1073/pnas.88.7.2869. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cockett M. I., Bebbington C. R., Yarranton G. T. High level expression of tissue inhibitor of metalloproteinases in Chinese hamster ovary cells using glutamine synthetase gene amplification. Biotechnology (N Y) 1990 Jul;8(7):662–667. doi: 10.1038/nbt0790-662. [DOI] [PubMed] [Google Scholar]
  7. Daugherty B. L., DeMartino J. A., Law M. F., Kawka D. W., Singer I. I., Mark G. E. Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins. Nucleic Acids Res. 1991 May 11;19(9):2471–2476. doi: 10.1093/nar/19.9.2471. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. DeNardo G. L., Kroger L. A., DeNardo S. J., Miers L. A., Salako Q., Kukis D. L., Fand I., Shen S., Renn O., Meares C. F. Comparative toxicity studies of yttrium-90 MX-DTPA and 2-IT-BAD conjugated monoclonal antibody (BrE-3). Cancer. 1994 Feb 1;73(3 Suppl):1012–1022. doi: 10.1002/1097-0142(19940201)73:3+<1012::aid-cncr2820731340>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  9. Deshpande S. V., DeNardo S. J., Kukis D. L., Moi M. K., McCall M. J., DeNardo G. L., Meares C. F. Yttrium-90-labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent. J Nucl Med. 1990 Apr;31(4):473–479. [PubMed] [Google Scholar]
  10. Hakimi J., Chizzonite R., Luke D. R., Familletti P. C., Bailon P., Kondas J. A., Pilson R. S., Lin P., Weber D. V., Spence C. Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys. J Immunol. 1991 Aug 15;147(4):1352–1359. [PubMed] [Google Scholar]
  11. Hale G., Dyer M. J., Clark M. R., Phillips J. M., Marcus R., Riechmann L., Winter G., Waldmann H. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet. 1988 Dec 17;2(8625):1394–1399. doi: 10.1016/s0140-6736(88)90588-0. [DOI] [PubMed] [Google Scholar]
  12. Harrison A., Walker C. A., Parker D., Jankowski K. J., Cox J. P., Craig A. S., Sansom J. M., Beeley N. R., Boyce R. A., Chaplin L. The in vivo release of 90Y from cyclic and acyclic ligand-antibody conjugates. Int J Rad Appl Instrum B. 1991;18(5):469–476. doi: 10.1016/0883-2897(91)90107-v. [DOI] [PubMed] [Google Scholar]
  13. Hnatowich D. J., Chinol M., Siebecker D. A., Gionet M., Griffin T., Doherty P. W., Hunter R., Kase K. R. Patient biodistribution of intraperitoneally administered yttrium-90-labeled antibody. J Nucl Med. 1988 Aug;29(8):1428–1435. [PubMed] [Google Scholar]
  14. Isaacs J. D., Watts R. A., Hazleman B. L., Hale G., Keogan M. T., Cobbold S. P., Waldmann H. Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet. 1992 Sep 26;340(8822):748–752. doi: 10.1016/0140-6736(92)92294-p. [DOI] [PubMed] [Google Scholar]
  15. Jones S. T., Bendig M. M. Rapid PCR-cloning of full-length mouse immunoglobulin variable regions. Biotechnology (N Y) 1991 Jan;9(1):88–89. doi: 10.1038/nbt0191-88. [DOI] [PubMed] [Google Scholar]
  16. King D. J., Adair J. R., Angal S., Low D. C., Proudfoot K. A., Lloyd J. C., Bodmer M. W., Yarranton G. T. Expression, purification and characterization of a mouse-human chimeric antibody and chimeric Fab' fragment. Biochem J. 1992 Jan 15;281(Pt 2):317–323. doi: 10.1042/bj2810317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. King D. J., Turner A., Farnsworth A. P., Adair J. R., Owens R. J., Pedley R. B., Baldock D., Proudfoot K. A., Lawson A. D., Beeley N. R. Improved tumor targeting with chemically cross-linked recombinant antibody fragments. Cancer Res. 1994 Dec 1;54(23):6176–6185. [PubMed] [Google Scholar]
  18. Kosmas C., Snook D., Gooden C. S., Courtenay-Luck N. S., McCall M. J., Meares C. F., Epenetos A. A. Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy. Cancer Res. 1992 Feb 15;52(4):904–911. [PubMed] [Google Scholar]
  19. Krause D., Shearman C., Lang W., Kanzy E. J., Kurrle R. Determination of affinities of murine and chimeric anti alpha/beta-T-cell receptor antibodies by flow cytometry. Behring Inst Mitt. 1990 Dec;(87):56–67. [PubMed] [Google Scholar]
  20. Larson S. M. Choosing the right radionuclide and antibody for intraperitoneal radioimmunotherapy. J Natl Cancer Inst. 1991 Nov 20;83(22):1602–1604. doi: 10.1093/jnci/83.22.1602. [DOI] [PubMed] [Google Scholar]
  21. LoBuglio A. F., Wheeler R. H., Trang J., Haynes A., Rogers K., Harvey E. B., Sun L., Ghrayeb J., Khazaeli M. B. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci U S A. 1989 Jun;86(11):4220–4224. doi: 10.1073/pnas.86.11.4220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Mountain A., Adair J. R. Engineering antibodies for therapy. Biotechnol Genet Eng Rev. 1992;10:1–142. doi: 10.1080/02648725.1992.10647886. [DOI] [PubMed] [Google Scholar]
  23. Sharkey R. M., Motta-Hennessy C., Pawlyk D., Siegel J. A., Goldenberg D. M. Biodistribution and radiation dose estimates for yttrium- and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts. Cancer Res. 1990 Apr 15;50(8):2330–2336. [PubMed] [Google Scholar]
  24. Stephens P. E., Cockett M. I. The construction of a highly efficient and versatile set of mammalian expression vectors. Nucleic Acids Res. 1989 Sep 12;17(17):7110–7110. doi: 10.1093/nar/17.17.7110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Stewart J. S., Hird V., Snook D., Dhokia B., Sivolapenko G., Hooker G., Papadimitriou J. T., Rowlinson G., Sullivan M., Lambert H. E. Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer. J Clin Oncol. 1990 Dec;8(12):1941–1950. doi: 10.1200/JCO.1990.8.12.1941. [DOI] [PubMed] [Google Scholar]
  26. Turner A., King D. J., Farnsworth A. P., Rhind S. K., Pedley R. B., Boden J., Boden R., Millican T. A., Millar K., Boyce B. Comparative biodistributions of indium-111-labelled macrocycle chimeric B72.3 antibody conjugates in tumour-bearing mice. Br J Cancer. 1994 Jul;70(1):35–41. doi: 10.1038/bjc.1994.246. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Watanabe N., Goodwin D. A., Meares C. F., McTigue M., Chaovapong W., Ransone C. M., Renn O. Immunogenicity in rabbits and mice of an antibody-chelate conjugate: comparison of (S) and (R) macrocyclic enantiomers and an acyclic chelating agent. Cancer Res. 1994 Feb 15;54(4):1049–1054. [PubMed] [Google Scholar]
  28. Welt S., Divgi C. R., Kemeny N., Finn R. D., Scott A. M., Graham M., Germain J. S., Richards E. C., Larson S. M., Oettgen H. F. Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol. 1994 Aug;12(8):1561–1571. doi: 10.1200/JCO.1994.12.8.1561. [DOI] [PubMed] [Google Scholar]
  29. Welt S., Divgi C. R., Real F. X., Yeh S. D., Garin-Chesa P., Finstad C. L., Sakamoto J., Cohen A., Sigurdson E. R., Kemeny N. Quantitative analysis of antibody localization in human metastatic colon cancer: a phase I study of monoclonal antibody A33. J Clin Oncol. 1990 Nov;8(11):1894–1906. doi: 10.1200/JCO.1990.8.11.1894. [DOI] [PubMed] [Google Scholar]
  30. Whittle N., Adair J., Lloyd C., Jenkins L., Devine J., Schlom J., Raubitschek A., Colcher D., Bodmer M. Expression in COS cells of a mouse-human chimaeric B72.3 antibody. Protein Eng. 1987 Dec;1(6):499–505. doi: 10.1093/protein/1.6.499. [DOI] [PubMed] [Google Scholar]
  31. Whitwell J. R., Spiers F. W. Calculated beta-ray dose factors for trabecular bone. Phys Med Biol. 1976 Jan;21(1):16–38. doi: 10.1088/0031-9155/21/1/002. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES